ADvantage Therapeutics has filed a notice of an exempt offering of securities to raise $25,449,956.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, ADvantage Therapeutics is raising $25,449,956.00 in new funding. Sources indicate that as part of senior management Chairman, Agustin Santana played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About ADvantage Therapeutics
ADvantage Therapeutics, Inc. is developing therapies to treat neurodegenerative conditions with a major focus on Alzheimers Disease (AD). We are currently preparing for Phase 2 clinical trials in Europe. Furthermore, ADvantage is developing potentially paradigm-changing therapies to treat AD in its labs at the Vienna BioCenter. Our work suggests that our lead therapeutic (AD04) regulates the immune system to provide patients with a unique positive effect on the course of Alzheimers Disease pathology. Our vision is to provide patients with a disease-modifying therapeutic for early Alzheimers Disease, thereby making the world a distinctly better place. Entrepreneurs at heart, we thrive taking on significant challenges and breaking new ground. In the words of Marie Curie, I was taught that the way of progress was neither swift nor easy.
To learn more about ADvantage Therapeutics, visit http://www.advantagetherapeutics.com/
Contact:
Agustin Santana, Chairman
305-846-9027
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.